Early Suppressive Effects of Chemotherapy on Recovery of Bone Marrow Megakaryocyte Precursors: Possible Relationship to Platelet Recovery

This study utilized a recently developed culture and quantitation system to detect megakaryocyte precursors in CD34+ bone marrow cells from normal donors and breast cancer patients treated with 5‐fluorouracil, leucovorin, adriamycin and cyclophosphamide (FLAC). Bone marrow was obtained from patients before and then after their first cycle of FLAC once blood cell counts had recovered. CD34+ cells were isolated and placed in liquid culture with growth factors to stimulate proliferation and lineage commitment. Absorbance values from an enzyme‐linked immunosorbent assay were used to quantitate expression of platelet glycoprotein GPIIb/IIIa. There was an increase in absorbance with increasing numbers of cells seeded per culture that was associated with an increase in the number of megakaryocyte lineage cells produced. After 10 days in liquid culture, absorbance values for expression of GPIIb/IIIa from 2,000 normal donor and pre‐chemotherapy CD34+ marrow cells were ≥ 1.0. Absorbance values from cultures of post‐chemotherapy CD34+ cells from four patients were similar to values from pre‐chemotherapy CD34+ cells. In contrast, absorbance values from cultures of post‐chemotherapy CD34+ cells from two other patients were low (absorbance <0.5). Low absorbance values for GPIIb/IIIa expression indicate that megakaryocyte production from those CD34+ cells was reduced. Both of those patients developed prolonged thrombocytopenia and platelet nadirs of less than 20,000/μI during FLAC chemotherapy. In contrast, only one out of four patients whose cultures of post‐chemotherapy CD34+ cells had absorbance values ≥ 1.0 developed platelet nadirs less than 20,000/μl. These results suggest that low platelet nadirs and delayed platelet recovery may be associated with suppressive effects of chemotherapy on recovery of megakaryocyte precursors.

[1]  M. Warren,et al.  Comparative Effects of Insulin‐Like Growth Factor II (IGF‐II) and IGF‐II Mutants Specific for IGF‐II/CIM6‐P or IGF‐I Receptors on in Vitro Hematopoiesis , 1996, Stem cells.

[2]  A. Tolcher,et al.  Prospective, randomized trial of 5-fluorouracil, leucovorin, doxorubicin, and cyclophosphamide chemotherapy in combination with the interleukin-3/granulocyte-macrophage colony-stimulating factor (GM-CSF) fusion protein (PIXY321) versus GM-CSF in patients with advanced breast cancer. , 1996, Blood.

[3]  J. O’Shaughnessy,et al.  Early suppressive effects of chemotherapy and cytokine treatment on committed versus primitive haemopoietic progenitors in patient bone marrow , 1996, British journal of haematology.

[4]  A. Tolcher,et al.  A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy , 1995 .

[5]  H. Deeg,et al.  Thrombocytopenia in dogs induced by granulocyte-macrophage colony-stimulating factor: increased destruction of circulating platelets. , 1995, Blood.

[6]  M. Warren,et al.  CD34+ cell expansion and expression of lineage markers during liquid culture of human progenitor cells , 1995, Stem cells.

[7]  D. Venzon,et al.  A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Peters Wp,et al.  Advances in the clinical use of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor to intensify cancer chemotherapy. , 1994 .

[9]  J. Bishop Platelet support and the use of cytokines , 1994, Stem cells.

[10]  G. Bonadonna,et al.  Increase in peripheral blood megakaryocyte progenitors following cancer therapy with high-dose cyclophosphamide and hematopoietic growth factors. , 1993, Experimental hematology.

[11]  G. Schwartz,et al.  Glycosylated insulin-like growth factor II promoted expansion of granulocyte-macrophage colony-forming cells in serum-deprived liquid cultures of human peripheral blood cells. , 1993, Experimental Hematology.

[12]  M. Seidman,et al.  A new culture and quantitation system for megakaryocyte growth using cord blood CD34+ cells and the GPIIb/IIIa marker. , 1993, Experimental hematology.

[13]  J. Arnold,et al.  Compensatory mechanisms in platelet production: lack of a paracrine response in W/Wv mice treated with 5-fluorouracil. , 1993, Experimental hematology.

[14]  R. Frenck,et al.  Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Green,et al.  Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Ebbe,et al.  5-fluorouracil-induced thrombocytosis in mice is independent of the spleen and can be partially reproduced by repeated doses of cytosine arabinoside. , 1989, Experimental hematology.

[17]  B. Coller,et al.  A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. , 1983, The Journal of clinical investigation.

[18]  P. Chervenick,et al.  Megakaryocytopoiesis and granulopoiesis following cyclophosphamide. , 1982, The Journal of laboratory and clinical medicine.

[19]  A. Yeager,et al.  Effects of cyclophosphamide on murine bone marrow and splenic megakaryocyte‐CFC, granulocyte‐macrophage‐CFC, and peripheral blood cell levels , 1982, Journal of cellular physiology.

[20]  S. Karpatkin Autoimmune thrombocytopenic purpura. , 1980, The American journal of the medical sciences.